Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Sex- and age-specific regulation of ACE2: Insights into severe COVID-19 susceptibility

Anissa Viveiros a,b, Mahmoud Gheblawi a, Preetinder K. Aujla a, Deanna K. Sosnowski c, John M. Seubert c,d, Zamaneh Kassiri a, Gavin Y. Oudit b,e,*

a Department of Physiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
b Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada
c Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
d Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
e Division of Cardiology, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada

ARTICLE INFO

Keywords:
COVID-19
Sex
Age
ACE2
TMPRSS2
Heart

ABSTRACT

Aged males disproportionately succumb to increased COVID-19 severity, hospitalization, and mortality compared to females. Angiotensin-converting enzyme 2 (ACE2) and transmembrane protease, serine 2 (TMPRSS2) facilitate SARS-CoV-2 viral entry and may have sexually dimorphic regulation. As viral load dictates disease severity, we investigated the expression, protein levels, and activity of ACE2 and TMPRSS2. Our data reveal that aged males have elevated ACE2 in both mice and humans across organs. We report the first comparative study comprehensively investigating the impact of sex and age in murine and human levels of ACE2 and TMPRSS2, to begin to elucidate the sex bias in COVID-19 severity.

Nonstandard abbreviations

ACE2 Angiotensin-converting enzyme
ADAM17 A disintegrin and metalloprotease 17
CVD cardiovascular disease
E2 17β-estradiol
miRNA Micro RNA
RAS Renin-angiotensin system
SI Small intestine
TMPRSS2 Transmembrane protease, serine 2

1. Introduction

The COVID-19 pandemic predominately finds aged males experiencing worsened disease severity and adverse outcomes [1]. Current experimental data are limited in explaining this sex bias. The SARS-CoV-2 virus predominantly hijacks two broadly-expressed endogenous proteins to facilitate infection, namely angiotensin-converting enzyme 2 (ACE2) and transmembrane protease, serine 2 (TMPRSS2) [2,3]. A meta-analysis of thirty-six clinical studies found that a higher viral load at symptom onset is associated with disease severity, ICU hospitalization, and mortality [4]. Therefore, it is likely that increased viral load confers susceptibility to severe COVID-19; thus, the sex discrepancy may result from differences in levels of viral entry factors.

ACE2 demonstrates sexually dimorphic expression dependent on sex chromosomes and sex hormones [1]. Interestingly, Ace2 is an X-linked gene that escapes X-chromosome inactivation, which may confer a “double-dosage” of ACE2 mRNA [1,2]. However, the female hormone 17β-estradiol (E2) reduces ACE2 expression in vitro, but does not affect TMPRSS2 [5]. In the kidney, basal ACE2 activity is reduced in females compared to males in an E2-dependent manner [6,7]. However, E2 upregulates ACE2 in a model of intrauterine growth restriction, thereby complicating the relationship between E2 and ACE2 in disease [8]. Further, ACE2 is regulated downstream by micro RNAs (miRNAs) and proteolytic cleavage [1]. Finally, the TMPRSS2 gene is positively regulated by androgens in the prostate, thus may demonstrate male-biased expression elsewhere [9]. In all, the regulation of ACE2 and TMPRSS2 are complex and organ-specific, and the role of sex and age have yet to be elucidated.

Our recent review highlights the global pattern of sex- and age-bias...
in COVID-19 severity to favor older males [1]. Here, we aimed to delineate the impact of sex and aging on the expression, protein levels, and activity of viral entry factors ACE2 and TMPRSS2 to begin to explain this discrepancy.

2. Materials and methods

2.1. Animal studies

Animals were maintained at the University of Alberta, and animal protocols were performed in compliance with the guidelines of the Animal Care and Use Committee and the Canadian Council of Animal Care. Kidney, lung, heart, and small intestine (SI) were harvested from male and female wild-type (WT) mice (background C57BL/6/J) at three months (young), twelve months (adult), and eighteen months of age (aged) under ketamine-xylazine anesthesia.

2.2. Human explanted hearts

Explanted human hearts were obtained following cardiopulmonary arrest according to the Human Organ Procurement and Exchange (HOPE) program protocol and approved by the Health Research Ethics Board of the University of Alberta. Transmural left ventricle specimens were procured from young (median age 23/23; M/F) and aged (median age 55/56; M/F) human donors with no history of cardiovascular disease (Supplementary Table S1).

2.3. Gene expression

RNA isolation from mouse and human tissue was performed by Trizol-chloroform extraction. Isolated RNA (1 μg) was reverse transcribed with random primers (Invitrogen), and cDNA synthesized using SuperScript® II Reverse Transcriptase (Invitrogen). Real-time quantitative PCR was performed with TaqMan premixed assays (ThermoFisher Scientific) for gene expression in mice for TMPRSS2 (Mm00443687_m1) and ACE2 (Mm01159009_m1), and in humans for ACE2 (Hs00222343_m1).

2.4. Immunoblot

Cross-sectional tissue sections from each organ were homogenized in Celllytically Lysis reagent (ThermoFisher) and normalized by bicinechinonic acid protein assay (BCA). Proteins were resolved by SDS-PAGE on a 12% gel and transferred to polyvinylidene fluoride membranes in transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol (pH 8.3)). Membranes were blocked in 5% non-fat milk and probed for ACE2 (Abcam) (1:1000) and TMPRSS2 (Abcam) (1:1000) in 5% bovine serum albumin (BSA). HRP-conjugated secondary antibodies (1:4000, CST) were used for detection. Lanes were normalized to MemCode™ total protein staining (ThermoFisher). Immunoreactivity was detected with Clarity™ Western ECL substrate (BioRad), and band densitometry measured with Image Studio (LI-COR Biosciences).

2.5. Immunofluorescence

Immunofluorescence was performed with Optimal Cutting Temperature (OCT)-embedded frozen transmural left ventricle tissue sections from both mice and humans. Sections were fixed in 4% paraformaldehyde, blocked with 4% BSA, and probed for ACE2 (R&D Systems) and NG2 (Abcam). Proteins were visualized with anti-goat Alexa-488 and anti-rabbit Alexa-594 secondary antibodies, respectively. Wheat Germ Agglutinin (WGA) conjugated to Alexa-405 (Invitrogen) was included to delineate the cell membrane.

2.6. ACE2 enzyme activity assay

ACE2 activity assays were performed as previously described with modification for tissue analysis [10]. Briefly, tissue lysates were normalized (2.3), and equal protein (150 μg heart/lung, 50 μg SI/kidney) was diluted in 1× Assay buffer (75 mM Tris, 5 mM ZnCl2, 1 M NaCl, pH 6.5) with protease inhibitors, including 10 μM captopril and 5 μM amastatin. Specificity was assessed by incubating samples in the presence and absence of ACE2 inhibitor DX-600 (Cayman Chemical) for thirty minutes. Fluorogenic Peptide Substrate VI (ES007, R&D Systems) was subsequently added (final concentration of 50 μM in Assay buffer), and kinetic measurements obtained immediately following (350/405 nm). Fluorogenic standards (R&D Systems) were run in parallel to generate a conversion factor (pmol/RFU) to calculate the specific activity of ACE2.

2.7. Statistical analysis

Statistics were performed using SPSS software and graphs plotted with GraphPad Prism. Data are represented as the mean ± SEM. Data that did not follow normal distribution were analyzed as independent samples with the Kruskal-Wallis test with pairwise comparison adjusted by Bonferroni correction. Two-way ANOVA with Tukey post hoc test was used to compare multiple groups. Unpaired student’s t-test was used to compare only two groups. *p < 0.05; **p < 0.01, ***p < 0.001. Alternate symbols may be used to indicate significance among different comparisons, but the number of symbols indicates the level of significance.

3. Results

Gene expression for Ace2 exhibits a tissue-specific pattern, with the highest expression in the small intestine (SI) and lowest expression in the heart (Fig. 1A), demonstrating a positive linear relationship with ACE2 protein levels and enzyme activity (Fig. 1B). In contrast, Tmprss2 mRNA is highest in the kidneys, whereas the highest TMPRSS2 protein level is in the SI, with undetectable mRNA and minimal protein in the heart (Fig. 1C).

To analyze the impact of sex and aging across organs, we first examined the molecular signature of ACE2 and TMPRSS2 in mice. In the heart, Ace2 mRNA was lowered in the aged animals (Fig. 1D) with a lack of a difference in ACE2 protein levels and activities between males and females within age groups; however, ACE2 activity was elevated in aged animals (Fig. 1E–F). In the lungs, Ace2 mRNA expression was higher in adult females, whereas protein levels and activity were reduced in the aged females compared to males (Fig. 1D–F). In the kidneys, ACE2 levels and activity were higher in males than females across all age groups, thus corroborating studies demonstrating increased renal ACE2 activity in male rats [7]. No differences in ACE2 were observed in the SI. In both organs, Ace2 mRNA expression did not show a sex-dependent variation (Fig. 1D–F). In contrast, TMPRSS2 mRNA and protein levels did not vary between sexes and with aging in the lungs and SI; however, adult females had increased expression in the kidneys compared to males (Fig. 1D–E).

SARS-CoV-2 infection facilitates the loss of membrane ACE2 following initial infection [2,11]. The high burden of cardiovascular disease (CVD) in COVID-19 patients and the critical role of ACE2 in myocardial and vascular protection highlights this pathophysiological connection; thus, we next focused on examining ACE2 in the heart [2,12]. To determine the age-related pattern of myocardial ACE2 across age groups, we first measured murine protein levels by immunoblot. ACE2 was elevated in aged males and females compared to the younger age groups (Fig. 2A), in accordance with ACE2 activity (Fig. 1F), yet in contrast to mRNA expression (Fig. 1D). Immunofluorescence demonstrated predominant pericyte and vascular distribution of ACE2 (colocalization with NG2) (Fig. 2B) [12]. We next analyzed young and aged
explained human heart samples. ACE2 protein levels were elevated in aged males but not in aged females, as confirmed by ACE2 immunofluorescence (Fig. 2C–D). Interestingly, no differences in Ace2 mRNA expression were discernable; however, ACE2 activity was consistent with the immunoblot results, in which aged males were elevated (Fig. 1F). Discordant mRNA and protein levels also characterized murine hearts (data not shown).

Fig. 2. Sex- and age-differences in ACE2 levels in mouse and human hearts.
A. Representative immunoblot of mouse hearts for ACE2 protein levels (n = 6 biological replicates/group). Three gels were compiled for quantification (Supplementary Fig. S4). Data are represented as the mean ± SEM and were analyzed by two-way ANOVA with Tukey post hoc test; *p < 0.05; **p < 0.01, ***p < 0.001. For all experiments, young animals (n = 12) were obtained from four litters and each litter was collected over two days. Adult and aged animals (n = 12/group) were obtained from five and three litters respectively, and each litter was collected over two days. B. Immunofluorescence of ACE2 (green) and pericyte marker NG2 (red). Wheat Germ Agglutinin (WGA) (blue) was used to delineate the cell membrane. Qualitative images were captured from n = 2 biological replicates and n = 16 (8 images/donor) technical replicates for each age group. C. Representative immunoblot for ACE2 in human hearts (n = 6, biological replicates/group). Two gels were compiled for quantification (Supplementary Fig. S4). Quantification represents the combined result from two western blots. Data are represented as the mean ± SEM and were analyzed by two-way ANOVA with Tukey post hoc test. * indicates differences from young males, and # indicates differences between aged males and aged females; *p < 0.05; **p < 0.01, ***p < 0.001 where the number of symbols indicates the level of significance. D. Immunofluorescence of ACE2 (green) and NG2 (red). WGA (blue) was used to delineate the cell membrane. Qualitative images were captured from n = 2 biological replicates and n = 16 (8 images/donor) technical replicates for each age group. E. ACE2 protein levels and activity are positively correlated, but not mRNA expression. * indicates differences from young males, and # indicates differences between aged males and aged females. *p < 0.05; **p < 0.01, ***p < 0.001 where the number of symbols indicates the level of significance. F. Schematic figure showing the multi-organ impact of sex and aging on ACE2 levels as a potential contributor to the increased male susceptibility to severe COVID-19. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

4. Discussion

In this study, our data reveal an organ-, sex- and age-dependent difference in ACE2 regulation, with increased ACE2 in the lungs and hearts of aged males, and with a sex- rather than an age-dependent pattern in the kidneys favoring males. These changes can contribute to the increased severity and adverse outcomes reported in male COVID-19 patients (Fig. 2F). As SARS-CoV-2 viral load is predictive of intensive care unit hospitalization and mortality [4,13], we propose that aged males may be at an elevated risk partly due to the higher initial viral burden driven by the increased tissue ACE2, thus subject to pulmonary, myocardial, and renal injury. However, additional studies are necessary to delineate the relationship between viral load and the levels of ACE2 (and TMPRSS2). Further, as we confirmed the low levels of TMPRSS2 in
the heart, other proteases, such as the cathepsins, may also facilitate spike protein priming and are worthy of investigation [3]. Our results also highlight that SARS-CoV-2 could target multiple organs beyond the respiratory system, including the heart, kidneys, and gut, mainly because ACE2 protein levels in these organs far exceed the levels in the lungs. In fact, gastrointestinal symptoms are common in COVID-19 patients and occasionally precede pulmonary manifestations [11].

While a positive relationship exists between protein levels and activity of ACE2, Ace2 mRNA and protein levels were uncoupled within organs. These findings, coupled with the observation that females have two functional copies of the X-linked Ace2 gene, suggest a complex mechanism of transcriptional, translational, and proteolytic control of ACE2 that counters the predicted female-biased expression [1]. For example, given the impact of E2 on ACE2 levels and activity, the levels of gonadal steroids may also influence the observed sex differences [6]. Besides sex hormone-dependent regulation, ACE2 protein levels are subject to posttranscriptional and posttranslational modulation, such as by proteolytic cleavage and miRNAs.

Proteolytic cleavage of ACE2 is linked to the pathogenesis of CVD [1,2]. Physiologically, ACE2 counteracts the canonical renin-angiotensin system (RAS), which promotes vasoconstriction and inflammation with angiotensin II as the effector molecule. Therefore, ACE2 is protective in CVD, where chronic elevation of the canonical RAS pathway is characterized [2]. A downstream consequence of RAS activity is the activation of a disintegrin and metalloprotease 17 (ADAM17), which cleaves and releases ACE2 from the plasma membrane. Therefore, aberrant canonical RAS and subsequent increase of ADAM17 activity generate soluble plasma ACE2, which is associated with detrimental outcomes in CVD [1,2]. Similarly, ADAM17-dependent ACE2 shedding may contribute to increased COVID-19 severity following initial viral endocytosis [2]. In accordance, increased plasma ACE2 is associated with worsened clinical outcomes in hospitalized COVID-19 patients [2,14].

Finally, another mechanism of posttranscriptional control occurs by miRNAs, which suppress gene expression. Organ-specific miRNAs are predicted in silico to target ACE2 mRNA based on transcript sequences [15], as well as validated experimentally in cardiomyocytes [16]. Therefore, the mechanisms of proteolytic cleavage and miRNAs further complicate the discourse on ACE2 regulation. Additional studies are required to delineate the contribution of miRNAs and proteolytic cleavage on ACE2 expression and activity. In addition, the regulation of ACE2 is complex, and the homeostatic mechanisms controlling ACE2 should be assessed for modulation in health versus disease. Given the discordance between mRNA expression and protein levels, we emphasize the complicated regulation of viral entry proteins. Further, we demonstrate the need to assess all levels from transcriptional to posttranslational to understand the biological consequences of all modes of regulation.

5. Conclusion

Our study highlights a novel sex- and age-specific bias in ACE2 protein levels and activity in the kidney, heart, and lung at basal conditions. To our knowledge, we present the first comparative analysis to comprehensively investigate the impact of sex and age on ACE2 and TMPRSS2 in both humans and mice. Given the global burden of the COVID-19 pandemic, our findings expand the knowledge of the tissue distribution of viral entry factors and begin to inform the sex-discrepancy in COVID-19 severity.

Declaration of Competing Interest

The authors have no conflict of interests to declare.

Acknowledgements

The authors acknowledge funding from the Canadian Institutes of Health Research (CIHR) and Heart and Stroke Foundation of Canada to GYO, and from the Heart and Stroke Foundation of Canada to JMS. The remaining authors have no funding sources to declare.

Appendix A. Supplementary data

Supplementary data to this article can be found at https://doi.org/10.1016/j.yjmcc.2021.11.003.

References

[1] A. Viveiros, J. Ramusson, J. Yu, S.L. Mulyavah, C.Y.Y. Yap, C.M. Norris, et al., Sex differences in COVID-19: candidate pathways, genetics of ACE2, and sex hormones, Am. J. Physiol. Heart Circ. Physiol. 320 (1) (2021) H296-H304.
[2] M. Gheblawi, K. Wang, A. Viveiros, Q. Nguyen, J.C. Zhong, A.J. Turner, et al., Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2, Circ. Res. 126 (10) (2020) 1456–1474.
[3] C. Muus, M.D. Lucekem, G. Eraslan, L. Sikkena, A. Weghagay, G. Heimberg, et al., Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics, Nat. Med. 27 (3) (2021) S46–S59.
[4] S. Shenoy, SARS-CoV-2 (COVID-19), viral load and clinical outcomes; lessons learned one year into the pandemic: a systematic review, World J. Crit. Care Med. 10 (4) (2021) 132–150.
[5] K.E. Stelzig, F. Canepa-Escaro, M. Schiliro, S. Berdnikovs, Y.S. Prakash, S. E. Chiarelli, Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells, Am. J. Physiol. Lung Cell Mol. Physiol. 318 (6) (2020) L1280-L1281.
[6] J. Liu, H. Ji, W. Zheng, X. Wu, J.J. Zhu, A.P. Arnold, et al., Sex differences in renal angiotensin converting enzyme 2 (ACE2) activity are 17beta-oestradiol-dependent and sex chromosome-independent, Biol. Sex Differ. 1 (1) (2010) 6.
[7] K.D. Pendergrass, N.T. Pirro, B.M. Westwood, C.M. Ferrari, K.B. Bronniman, M. C. Chappell, Sex differences in circulating and renal angiotensins of hypertensive mRen(2) Lewis but not normotensive Lewis rats, Am. J. Physiol. Heart Circ. Physiol. 295 (1) (2008) H110-H120.
[8] N.B. Ojeda, D. Grigore, E.B. Robertson, B.T. Alexander, Estrogen protects against increased blood pressure in postpubertal female growth restricted offspring, Hypertension 50 (4) (2007) 679-685.
[9] R. Li, C. Ferguson, J.T. White, S. Wang, R. Veselka, L.D. True, et al., Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2, Cancer Res. 59 (17) (1999) 4180-4184.
[10] S. Epelman, W.H. Tang, S.Y. Chen, P. Van Lente, G.S. Francis, S. Sen. Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system, J. Am. Coll. Cardiol. 52 (9) (2008) 750–754.
[11] R.K. Sharma, B.R. Stevens, A.G. Obukhov, M.B. Grant, G.Y. Oudrit, Q. Li, et al., ACE2 (angiotensin-converting enzyme 2) in cardiopulmonary diseases: ramifications for the control of SARS-CoV-2, Hypertension 76 (3) (2020) 651–661.
[12] N.H. Tucker, M. Chaffin, K.C. Bedi Jr., I. Papangeli, A.D. Akkad, A. Aridhi, et al., Myocyte-specific upregulation of ACE2 in cardiovascular disease: implications for SARS-CoV-2-mediated myocarditis, Circulation 142 (7) (2020) 708–710.
[13] J. Fajnzylber, J. Regan, K. Coxen, H. Corry, C. Wong, A. Rosenthal, et al., SARS-CoV-2 viral load is associated with increased disease severity and mortality, Nat. Commun. 11 (1) (2020) 5493.
[14] T.W. Kragstrup, H.S. Grundberg, A.L. Nielsen, F. Rivellese, A. Mehta, et al., Plasma ACE2 predicts outcome of COVID-19 in hospitalized patients, PLoS One 16 (6) (2021), e0252799.
[15] S. Neriinian, M. Shkurnov, A. Turchinovich, E. Knyazev, A. Tonevitsky, Integrative analysis of mRNA and mRNA sequencing data reveals potential regulatory mechanisms of ACE2 and TMPRSS2, PLoS One 15 (7) (2020), e0235987.
[16] D. Lu, S. Chatterjee, K. Xiao, I. Riedel, Y. Wang, R. Foo, et al., MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocytes, J. Mol. Cell. Cardiol. 148 (2020) 46–49.